Glycoengineering Services

Glycosylation is particularly important for protein function and is directly responsible for recombinant biopharmaceutical immunogenicity. Knowledge of glycosylation provides opportunities for designing glycans via genetic engineering in a wide variety of cell types and chemoenzymatic engineering. Equipped with world-leading technology platforms and professional scientific staff in glycoengineering of proteins and antibodies, Creative Biolabs is fully competent and dedicated to serving as your one-stop-shop for glycoengineering services.

The Importance of Glycosylation

Fig.1 Strategies for N-glycan engineering. (Dicker, 2015)

Glycosylation, which is the enzymatic coupling of glycans to proteins and lipids, is the most widespread posttranslational modification (PTM). About 50% of all human proteins are glycosylated. However, since glycosylation is not template-driven and combinatorial modification of the types and numbers of glycans is possible, each single glycoprotein is invariably present as a heterogeneous array of glycoforms, thus significantly increasing the diversity of the proteome. The glycoform profile of a glycoprotein plays important roles in the process of protein transportation, including directing the product to the cytoplasm, nucleus, cell surface, or marking it for secretion. Moreover, changes in glycosylation cause diverse diseases, and variations in the glycosylation profile of proteins have been identified as disease markers as well.

Biopharmaceuticals are increasingly dominating the biopharmaceutical industry pipelines. The larger and larger market size of glycoproteins makes glycosylation a critical factor in drug development that cannot be ignored by biopharmaceutical research. The demonstration of glycoform heterogeneity and differences in biologic activity associated with defined glycoforms has demanded control over the production process. Increased understanding of the functions of individual glycoforms has motivated glycoengineering to produce individual glycoforms and the generation of “bio-better” therapeutics.

Glycoengineering Service at Creative Biolabs

Glyco-engineered expression platform is an important strategy to improve biopharmaceuticals. A better control of the factors leading to glycan heterogeneity will simplify the process of production of recombinant glycoprotein with less variation in terms of glycosylation.

With proven experience in glycoscience, Creative Biolabs has accumulated substantial experience and expertise in cell line glycoengineering. By assembling top-class scientific experts and integrating state-of-the-art technologies, Creative Biolabs has established several efficient glycoengineered expression platforms, including glycoengineered mammalian cell expression system, glycoengineered pichia pastoris expression system, and glycoengineered plant-based expression system. Our expression platforms can provide a completely new class of therapeutic glycoprotein with customized functions. Besides in vivo glycoengineering in different expression systems, we also employ chemoenzymatic method for glycoengineering of antibody in vitro.

Highlights

• Highly efficient in vivo glycoengineered expression platforms
• In vitro chemoenzymatic strategy
• Top-class scientific experts and integrating state-of-the-art technologies
• High flexibility and cost-effectiveness

We offer turn-key or ala carte services customized to our clients’ needs. Please contact us for more information and a detailed quote.

Reference

1. Dicker, M.; Strasser, R. Using glycol-engineering to produce therapeutic proteins. Expert opinion on biological therapy. 2015, 15(10): 1501-16.

Related Services:

1. Custom Synthesis Services
2. Therapeutic Glycoprotein Development Services
3. Glycoprotein Analysis Services
4. Carbohydrate Analysis Services
5. Glycan Modification and Labeling Services
6. Glycoconjugation Service
7. Bioactive Carbohydrates Screening Services
8. Tumor Glyco-diag Services
9. Anti-Glycoprotein Antibody Development Service
10. Glyco-based Vaccine Development Services
11. Glycoproteomics-based Liquid-biopsy LDT Development Services